a pre-clinical stage novel bispecific antibody directed against “both TSLP and IL4R,” used to treat conditions like atopic dermatitis. The private placement includes over 35.55 million shares ...

BSI-502, a bispecific antibody targeting TSLP and IL4R, is in the pre-clinical stage. In a completed, proof-of-concept, single-arm Phase IIa study, BSI-045B demonstrated a pharmacodynamic profile ...